Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation

OncoImmunology

Volumn 2, Issue 1, 2013, Pages

  Adler, Adam J ^a   Vella, Anthony T ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

CD134; CD137; CD4 T cell; Dual costimulation; Immunotherapy

Indexed keywords

CD134 ANTIGEN; CD137 ANTIGEN; CD40 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; OX40 LIGAND; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIGEN RECOGNITION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; LYMPHOCYTE SUBPOPULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84886945019     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22837     Document Type: Review

References (190)

1. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al.; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355:2408-17; PMID:17151364; http://dx.doi.org/10.1056/NEJMoa062867.
2. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-19; PMID:20818844; http://dx.doi.org/10.1056/NEJMoa1002011.
3. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396:643-9; PMID:9872311; http://dx.doi.org/10.1038/25292.
4. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011; 144:27-40; PMID:21215367; http://dx.doi.org/10.1016/j.cell.2010.11.055.
5. Srivastava N, Srivastava PK. Modeling the repertoire of true tumor-specific MHC I epitopes in a human tumor. PLoS One 2009; 4:e6094; PMID:19593447; http://dx.doi.org/10.1371/journal.pone.0006094.
6. Schatz DG, Oettinger MA, Schlissel MS. V(D)J recombination: molecular biology and regulation. Annu Rev Immunol 1992; 10:359-83; PMID:1590991; http://dx.doi.org/10.1146/annurev.iy.10.040192.002043.
7. Nikolich-Žugich J, Slifka MK, Messaoudi I. The many important facets of T-cell repertoire diversity. Nat Rev Immunol 2004; 4:123-32; PMID:15040585; http://dx.doi.org/10.1038/nri1292.
8. Bevan MJ. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004; 4:595-602; PMID:15286726; http://dx.doi.org/10.1038/nri1413.
9. King C, Tangye SG, Mackay CR. T follicular helper (TFH) cells in normal and dysregulated immune responses. Annu Rev Immunol 2008; 26:741-66; PMID:18173374; http://dx.doi.org/10.1146/annurev. immunol.26.021607.090344.
10. Khader SA, Gaffen SL, Kolls JK. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol 2009; 2:403-11; PMID:19587639; http://dx.doi.org/10.1038/mi.2009.100.
11. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 2010; 28:445-89; PMID:20192806; http://dx.doi.org/10.1146/annurev-immunol-030409-101212.
12. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982; 155:1063-74; PMID:6460831; http://dx.doi.org/10.1084/jem.155.4.1063.
13. North RJ, Awwad M. Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma. Immunology 1990; 71:90-5; PMID:2145216.
14. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-64; PMID:7636184.
15. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-61; PMID:12522256; http://dx.doi.org/10.1126/science.1079490.
16. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4:330-6; PMID:12612578; http://dx.doi.org/10.1038/ni904.
17. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000; 101:455-8; PMID:10850488; http://dx.doi.org/10.1016/S0092-8674(00)80856-9.
18. Shevach EM. Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 2001; 193:F41-6; PMID:11390442; http://dx.doi.org/10.1084/jem.193.11.F41.
19. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9; PMID:15322536; http://dx.doi.org/10.1038/nm1093.
20. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102:18538-43; PMID:16344461; http://dx.doi.org/10.1073/pnas.0509182102.
21. Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, et al. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J Exp Med 2005; 201:779-91; PMID:15753211; http://dx.doi.org/10.1084/jem.20041684.
22. Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007; 27:635-46; PMID:17919943; http://dx.doi.org/10.1016/j.immuni. 2007.08.014.
23. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13:828-35; PMID:17603493; http://dx.doi.org/10.1038/nm1609.
24. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010; 22:231-7; PMID:20144856; http://dx.doi.org/10.1016/j.coi.2010.01.009.
25. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175.
26. Kappler JW, Roehm N, Marrack P. T cell tolerance by clonal elimination in the thymus. Cell 1987; 49:273-80; PMID:3494522; http://dx.doi.org/10.1016/0092-8674(87)90568-X.
27. Hogquist KA, Baldwin TA, Jameson SC. Central tolerance: learning self-control in the thymus. Nat Rev Immunol 2005; 5:772-82; PMID:16200080; http://dx.doi.org/10.1038/nri1707.
28. Krueger A, Fas SC, Baumann S, Krammer PH. The role of CD95 in the regulation of peripheral T-cell apoptosis. Immunol Rev 2003; 193:58-69; PMID:12752671; http://dx.doi.org/10.1034/j.1600-065X.2003.00047.x.
29. Schwartz RH. T cell anergy. Annu Rev Immunol 2003; 21:305-34; PMID:12471050; http://dx.doi.org/10.1146/annurev.immunol.21.120601.141110.
30. Webb S, Morris C, Sprent J. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell 1990; 63:1249-56; PMID:2148123; http://dx.doi.org/10.1016/0092-8674(90)90420-J.
31. Rocha B, von Boehmer H. Peripheral selection of the T cell repertoire. Science 1991; 251:1225-8; PMID:1900951; http://dx.doi.org/10.1126/science. 1900951.
32. Jooss K, Gjata B, Danos O, von Boehmer H, Sarukhan A. Regulatory function of in vivo anergized CD4(+) T cells. Proc Natl Acad Sci U S A 2001; 98:8738-43; PMID:11438696; http://dx.doi.org/10.1073/pnas.151088898.
33. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52; PMID:9521319; http://dx.doi.org/10.1038/32588.
34. Jenkins MK, Khoruts A, Ingulli E, Mueller DL, McSorley SJ, Reinhardt RL, et al. In vivo activation of antigen-specific CD4 T cells. Annu Rev Immunol 2001; 19:23-45; PMID:11244029; http://dx.doi.org/10.1146/annurev.immunol.19.1.23.
35. Janeway CA Jr., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20:197-216; PMID:11861602; http://dx.doi.org/10.1146/annurev. immunol.20.083001.084359.
36. Jenkins MK, Taylor PS, Norton SD, Urdahl KB. CD28 delivers a costimulatory signal involved in antigenspecific IL-2 production by human T cells. J Immunol 1991; 147:2461-6; PMID:1717561.
37. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992; 356:607-9; PMID:1313950; http://dx.doi.org/10.1038/356607a0.
38. Norton SD, Zuckerman L, Urdahl KB, Shefner R, Miller J, Jenkins MK. The CD28 ligand, B7, enhances IL-2 production by providing a costimulatory signal to T cells. J Immunol 1992; 149:1556-61; PMID:1380533.
39. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol 2003; 3:609-20; PMID:12974476; http://dx.doi.org/10.1038/nri1148.
40. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005; 23:23-68; PMID:15771565; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115839.
41. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194:769-79; PMID:11560993; http://dx.doi.org/10.1084/jem.194.6.769.
42. Kurts C, Cannarile M, Klebba I, Brocker T. Dendritic cells are sufficient to cross-present self-antigens to CD8 T cells in vivo. J Immunol 2001; 166:1439-42; PMID:11160180.
43. Hagymasi AT, Slaiby AM, Mihalyo MA, Qui HZ, Zammit DJ, Lefrancois L, et al. Steady state dendritic cells present parenchymal self-antigen and contribute to, but are not essential for, tolerization of naive and Th1 effector CD4 cells. J Immunol 2007; 179:1524-31; PMID:17641018.
44. Luckashenak N, Schroeder S, Endt K, Schmidt D, Mahnke K, Bachmann MF, et al. Constitutive crosspresentation of tissue antigens by dendritic cells controls CD8+ T cell tolerance in vivo. Immunity 2008; 28:521-32; PMID:18387832; http://dx.doi.org/10.1016/j.immuni.2008.02.018.
45. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56:21-6; PMID:8548765.
46. Heslop HE, Rooney CM. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev 1997; 157:217-22; PMID:9255632; http://dx.doi.org/10.1111/j.1600-065X.1997.tb00984.x.
47. Brichard V, Van Pel A, Wölfel T, Wölfel C, De Plaen E, Lethé B, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993; 178:489-95; PMID:8340755; http://dx.doi.org/10.1084/jem.178.2.489.
48. Kang X, Kawakami Y, el-Gamil M, Wang R, Sakaguchi K, Yannelli JR, et al. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumorinfiltrating lymphocytes. J Immunol 1995; 155:1343-8; PMID:7543520.
49. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 1996; 184:2207-16; PMID:8976176; http://dx.doi.org/10.1084/jem.184.6.2207.
50. Bloom MB, Perry-Lalley D, Robbins PF, Li Y, el-Gamil M, Rosenberg SA, et al. Identification of tyrosinaserelated protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 1997; 185:453-9; PMID:9053445; http://dx.doi.org/10.1084/jem.185.3.453.
51. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994; 264:716-9; PMID:7513441; http://dx.doi.org/10.1126/science.7513441.
52. Bakker AB, Schreurs MW, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, et al. Melanocyte lineagespecific antigen gp100 is recognized by melanomaderived tumor-infiltrating lymphocytes. J Exp Med 1994; 179:1005-9; PMID:8113668; http://dx.doi.org/10.1084/jem.179.3.1005.
53. Bowne WB, Srinivasan R, Wolchok JD, Hawkins WG, Blachere NE, Dyall R, et al. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 1999; 190:1717-22; PMID:10587362; http://dx.doi.org/10.1084/jem.190.11.1717.
54. Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CE, Chan CC, et al. Vaccination with a recombinant vaccinia virus encoding a "self "antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A 1999; 96:2982-7; PMID:10077623; http://dx.doi.org/10.1073/pnas.96.6.2982.
55. Morgan DJ, Kreuwel HT, Fleck S, Levitsky HI, Pardoll DM, Sherman LA. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol 1998; 160:643-51; PMID:9551898.
56. Colella TA, Bullock TN, Russell LB, Mullins DW, Overwijk WW, Luckey CJ, et al. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med 2000; 191:1221-32; PMID:10748239; http://dx.doi.org/10.1084/jem.191.7.1221.
57. Nichols LA, Chen Y, Colella TA, Bennett CL, Clausen BE, Engelhard VH. Deletional self-tolerance to a melanocyte/melanoma antigen derived from tyrosinase is mediated by a radio-resistant cell in peripheral and mesenteric lymph nodes. J Immunol 2007; 179:993-1003; PMID:17617591.
58. Hu J, Kindsvogel W, Busby S, Bailey MC, Shi YY, Greenberg PD. An evaluation of the potential to use tumor-associated antigens as targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J Exp Med 1993; 177:1681-90; PMID:8496686; http://dx.doi.org/10.1084/jem.177.6.1681.
59. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, et al. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A 1998; 95:1178-83; PMID:9448305; http://dx.doi.org/10.1073/pnas.95.3.1178.
60. Shrikant P, Khoruts A, Mescher MF. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 1999; 11:483-93; PMID:10549630; http://dx.doi.org/10.1016/S1074-7613(00)80123-5.
61. Schell TD, Knowles BB, Tevethia SS. Sequential loss of cytotoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas. Cancer Res 2000; 60:3002-12; PMID:10850449.
62. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005; 437:141-6; PMID:16136144; http://dx.doi.org/10.1038/nature03954.
63. Sotomayor EM, Borrello I, Rattis FM, Cuenca AG, Abrams J, Staveley-O'Carroll K, et al. Crosspresentation of tumor antigens by bone marrowderived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 2001; 98:1070-7; PMID:11493453; http://dx.doi.org/10.1182/blood. V98.4.1070.
64. Mihalyo MA, Hagymasi AT, Slaiby AM, Nevius EE, Adler AJ. Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis. Prostate 2007; 67:536-46; PMID:17221844; http://dx.doi.org/10.1002/pros.20549.
65. Nguyen LT, Elford AR, Murakami K, Garza KM, Schoenberger SP, Odermatt B, et al. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med 2002; 195:423-35; PMID:11854356; http://dx.doi.org/10.1084/jem.20010032.
66. Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 2000; 13:265-76; PMID:10981969; http://dx.doi.org/10.1016/S1074-7613(00)00026-1.
67. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001; 411:1058-64; PMID:11429607; http://dx.doi.org/10.1038/35082583.
68. Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF, et al. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 2002; 17:737-47; PMID:12479820; http://dx.doi.org/10.1016/S1074-7613(02)00480-6.
69. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK. Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 2000; 12:1539-46; PMID:11058573; http://dx.doi.org/10.1093/intimm/12.11.1539.
70. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425:516-21; PMID:14520412; http://dx.doi.org/10.1038/nature01991.
71. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-9; PMID:17704786; http://dx.doi.org/10.1038/nm1622.
72. Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol 2003; 21:807-39; PMID:12615893; http://dx.doi.org/10.1146/annurev. immunol.21.120601.141135.
73. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991-8; PMID:12407406; http://dx.doi.org/10.1038/ni1102-991.
74. Zhou G, Lu Z, McCadden JD, Levitsky HI, Marson AL. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med 2004; 200:1581-92; PMID:15596524; http://dx.doi.org/10.1084/jem.20041240.
75. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5:677-85; PMID:10371507; http://dx.doi.org/10.1038/9525.
76. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184:747-52; PMID:8760829; http://dx.doi.org/10.1084/jem.184.2.747.
77. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393:478-80; PMID:9624004; http://dx.doi.org/10.1038/30996.
78. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393:480-3; PMID:9624005; http://dx.doi.org/10.1038/31002.
79. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393:474-8; PMID:9624003; http://dx.doi.org/10.1038/30989.
80. Maxwell JR, Campbell JD, Kim CH, Vella AT. CD40 activation boosts T cell immunity in vivo by enhancing T cell clonal expansion and delaying peripheral T cell deletion. J Immunol 1999; 162:2024-34; PMID:9973474.
81. Sotomayor EM, Borrello I, Tubb E, Rattis FM, Bien H, Lu Z, et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med 1999; 5:780-7; PMID:10395323; http://dx.doi.org/10.1038/10503.
82. Diehl L, den Boer AT, Schoenberger SP, van der Voort EI, Schumacher TN, Melief CJ, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med 1999; 5:774-9; PMID:10395322; http://dx.doi.org/10.1038/10495.
83. Mallett S, Fossum S, Barclay AN. Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes--a molecule related to nerve growth factor receptor. EMBO J 1990; 9:1063-8; PMID:2157591.
84. Gramaglia I, Weinberg AD, Lemon M, Croft M. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 1998; 161:6510-7; PMID:9862675.
85. Murata K, Ishii N, Takano H, Miura S, Ndhlovu LC, Nose M, et al. Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand. J Exp Med 2000; 191:365-74; PMID:10637280; http://dx.doi.org/10.1084/jem.191.2.365.
86. Flynn S, Toellner KM, Raykundalia C, Goodall M, Lane P. CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J Exp Med 1998; 188:297-304; PMID:9670042; http://dx.doi.org/10.1084/jem.188.2.297.
87. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 2001; 15:445-55; PMID:11567634; http://dx.doi.org/10.1016/S1074-7613(01)00191-1.
88. So T, Song J, Sugie K, Altman A, Croft M. Signals from OX40 regulate nuclear factor of activated T cells c1 and T cell helper 2 lineage commitment. Proc Natl Acad Sci U S A 2006; 103:3740-5; PMID:16501042; http://dx.doi.org/10.1073/pnas.0600205103.
89. Maxwell JR, Weinberg A, Prell RA, Vella AT. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol 2000; 164:107-12; PMID:10605000.
90. Weatherill AR, Maxwell JR, Takahashi C, Weinberg AD, Vella AT. OX40 ligation enhances cell cycle turnover of Ag-activated CD4 T cells in vivo. Cell Immunol 2001; 209:63-75; PMID:11414737; http://dx.doi.org/10.1006/cimm.2001.1783.
91. Lathrop SK, Huddleston CA, Dullforce PA, Montfort MJ, Weinberg AD, Parker DC. A signal through OX40 (CD134) allows anergic, autoreactive T cells to acquire effector cell functions. J Immunol 2004; 172:6735-43; PMID:15153490.
92. Huddleston CA, Weinberg AD, Parker DC. OX40 (CD134) engagement drives differentiation of CD4+ T cells to effector cells. Eur J Immunol 2006; 36:1093-103; PMID:16541471; http://dx.doi.org/10.1002/eji.200535637.
93. Redmond WL, Gough MJ, Charbonneau B, Ratliff TL, Weinberg AD. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J Immunol 2007; 179:7244-53; PMID:18025166.
94. Bandyopadhyay S, Long M, Qui HZ, Hagymasi AT, Slaiby AM, Mihalyo MA, et al. Self-antigen prevents CD8 T cell effector differentiation by CD134 and CD137 dual costimulation. J Immunol 2008; 181:7728-37; PMID:19017962.
95. Weinberg AD, Rivera MM, Prell R, Morris A, Ramstad T, Vetto JT, et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 2000; 164:2160-9; PMID:10657670.
96. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellström KE, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997; 3:682-5; PMID:9176498; http://dx.doi.org/10.1038/nm0697-682.
97. Roberts DJ, Franklin NA, Kingeter LM, Yagita H, Tutt AL, Glennie MJ, et al. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells. J Immunother 2010; 33:769-79; PMID:20842060; http://dx.doi.org/10.1097/CJI.0b013e3181ee238f.
98. Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, Merghoub T, et al. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res 2006; 66:4904-12; PMID:16651447; http://dx.doi.org/10.1158/0008-5472.CAN-05-2813.
99. Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD. Science gone translational: the OX40 agonist story. Immunol Rev 2011; 244:218-31; PMID:22017441; http://dx.doi.org/10.1111/j.1600-065X.2011.01069.x.
100. Snell LM, Lin GH, McPherson AJ, Moraes TJ, Watts TH. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy. Immunol Rev 2011; 244:197-217; PMID:22017440; http://dx.doi.org/10.1111/j.1600-065X.2011.01063.x.
101. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3:745-56; PMID:12949498; http://dx.doi.org/10.1038/nri1184.
102. Kopf M, Ruedl C, Schmitz N, Gallimore A, Lefrang K, Ecabert B, et al. OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection. Immunity 1999; 11:699-708; PMID:10626892; http://dx.doi.org/10.1016/S1074-7613(00)80144-2.
103. Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol 2000; 165:3043-50; PMID:10975814.
104. Dawicki W, Bertram EM, Sharpe AH, Watts TH. 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. J Immunol 2004; 173:5944-51; PMID:15528328.
105. Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak AW, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997; 186:47-55; PMID:9206996; http://dx.doi.org/10.1084/jem.186.1.47.
106. Pollok KE, Kim Y-J, Zhou Z, Hurtado J, Kim KK, Pickard RT, et al. Inducible T cell antigen 4-1BB. Analysis of expression and function. J Immunol 1993; 150:771-81; PMID:7678621.
107. Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 1999; 162:5037-40; PMID:10227968.
108. Dawicki W, Watts TH. Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo. Eur J Immunol 2004; 34:743-51; PMID:14991604; http://dx.doi.org/10.1002/eji.200324278.
109. Tewalt EF, Cohen JN, Rouhani SJ, Guidi CJ, Qiao H, Fahl SP, et al. Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood 2012; 120:4772-82; PMID:22993390; http://dx.doi.org/10.1182/blood-2012-04-427013.
110. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 1998; 190:167-72; PMID:9878117; http://dx.doi.org/10.1006/cimm.1998.1396.
111. Futagawa T, Akiba H, Kodama T, Takeda K, Hosoda Y, Yagita H, et al. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol 2002; 14:275-86; PMID:11867564; http://dx.doi.org/10.1093/intimm/14.3.275.
112. Kwon B, Lee HW, Kwon BS. New insights into the role of 4-1BB in immune responses: beyond CD8+ T cells. Trends Immunol 2002; 23:378-80; PMID:12133793; http://dx.doi.org/10.1016/S1471-4906(02)02263-9.
113. Pauly S, Broll K, Wittmann M, Giegerich G, Schwarz H. CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal centers. J Leukoc Biol 2002; 72:35-42; PMID:12101260.
114. Myers LM, Vella AT. Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulation. Trends Immunol 2005; 26:440-6; PMID:15979409; http://dx.doi.org/10.1016/j. it.2005.06.003.
115. Hildebrand JM, Yi Z, Buchta CM, Poovassery J, Stunz LL, Bishop GA. Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions. Immunol Rev 2011; 244:55-74; PMID:22017431; http://dx.doi.org/10.1111/j.1600-065X.2011.01055.x.
116. Stamenkovic I, Clark EA, Seed B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J 1989; 8:1403-10; PMID:2475341.
117. Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 1993; 178:669-74; PMID:7688031; http://dx.doi.org/10.1084/jem.178.2.669.
118. Inaba K, Witmer-Pack M, Inaba M, Hathcock KS, Sakuta H, Azuma M, et al. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med 1994; 180:1849-60; PMID:7525841; http://dx.doi.org/10.1084/jem.180.5.1849.
119. Vu MD, Xiao X, Gao W, Degauque N, Chen M, Kroemer A, et al. OX40 costimulation turns off Foxp3+ Tregs. Blood 2007; 110:2501-10; PMID:17575071; http://dx.doi.org/10.1182/blood-2007-01-070748.
120. Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, Mittler RS, et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 2006; 12:693-8; PMID:16680149; http://dx.doi.org/10.1038/nm1405.
121. Lee SJ, Myers L, Muralimohan G, Dai J, Qiao Y, Li Z, et al. 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. J Immunol 2004; 173:3002-12; PMID:15322159.
122. Munks MW, Mourich DV, Mittler RS, Weinberg AD, Hill AB. 4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine. Immunology 2004; 112:559-66; PMID:15270726; http://dx.doi.org/10.1111/j.1365-2567.2004.01917.x.
123. Cuadros C, Dominguez AL, Lollini PL, Croft M, Mittler RS, Borgström P, et al. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice. Int J Cancer 2005; 116:934-43; PMID:15856473; http://dx.doi.org/10.1002/ijc.21098.
124. Gray JC, French RR, James S, Al-Shamkhani A, Johnson PW, Glennie MJ. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies. Eur J Immunol 2008; 38:2499-511; PMID:18792403; http://dx.doi.org/10.1002/eji.200838208.
125. Lee SJ, Rossi RJ, Lee SK, Croft M, Kwon BS, Mittler RS, et al. CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent. J Immunol 2007; 179:2203-14; PMID:17675480.
126. Qui HZ, Hagymasi AT, Bandyopadhyay S, St Rose MC, Ramanarasimhaiah R, Ménoret A, et al. CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation. J Immunol 2011; 187:3555-64; PMID:21880986; http://dx.doi.org/10.4049/jimmunol.1101244.
127. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002; 2:933-44; PMID:12461566; http://dx.doi.org/10.1038/nri954.
128. Glimcher LH, Townsend MJ, Sullivan BM, Lord GM. Recent developments in the transcriptional regulation of cytolytic effector cells. Nat Rev Immunol 2004; 4:900-11; PMID:15516969; http://dx.doi.org/10.1038/nri1490.
129. Misko IS, Pope JH, Hütter R, Soszynski TD, Kane RG. HLA-DR-antigen-associated restriction of EBV-specific cytotoxic T-cell colonies. Int J Cancer 1984; 33:239-43; PMID:6319303; http://dx.doi.org/10.1002/ijc.2910330212.
130. Williams NS, Engelhard VH. Identification of a population of CD4+ CTL that utilizes a perforin- rather than a Fas ligand-dependent cytotoxic mechanism. J Immunol 1996; 156:153-9; PMID:8598456.
131. Appay V, Zaunders JJ, Papagno L, Sutton J, Jaramillo A, Waters A, et al. Characterization of CD4(+) CTLs ex vivo. J Immunol 2002; 168:5954-8; PMID:12023402.
132. Jellison ER, Kim SK, Welsh RM. Cutting edge: MHC class II-restricted killing in vivo during viral infection. J Immunol 2005; 174:614-8; PMID:15634878.
133. Swain SL, McKinstry KK, Strutt TM. Expanding roles for CD4+ T cells in immunity to viruses. Nat Rev Immunol 2012; 12:136-48; PMID:22266691.
134. Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y, et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci U S A 1994; 91:9461-5; PMID:7937789; http://dx.doi.org/10.1073/pnas.91.20.9461.
135. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995; 16:487-94; PMID:7576053; http://dx.doi.org/10.1016/0167-5699(95)80033-6.
136. Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, et al. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010; 207:651-67; PMID:20156973; http://dx.doi.org/10.1084/jem.20091921.
137. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207:637-50; PMID:20156971; http://dx.doi.org/10.1084/jem.20091918.
138. Pearce EL, Mullen AC, Martins GA, Krawczyk CM, Hutchins AS, Zediak VP, et al. Control of effector CD8+ T cell function by the transcription factor Eomesodermin. Science 2003; 302:1041-3; PMID:14605368; http://dx.doi.org/10.1126/science. 1090148.
139. Intlekofer AM, Takemoto N, Wherry EJ, Longworth SA, Northrup JT, Palanivel VR, et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol 2005; 6:1236-44; PMID:16273099; http://dx.doi.org/10.1038/ni1268.
140. Maeurer MJ, Gollin SM, Martin D, Swaney W, Bryant J, Castelli C, et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 1996; 98:1633-41; PMID:8833913; http://dx.doi.org/10.1172/JCI118958.
141. Jäger E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jäger D, et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997; 71:142-7; PMID:9139833; http://dx.doi.org/0.1002/(SICI)1097-0215(19970410)71:2.142::AID-IJC3.3.0.CO;2-0.
142. Gottschalk S, Ng CY, Perez M, Smith CA, Sample C, Brenner MK, et al. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001; 97:835-43; PMID:11159505; http://dx.doi.org/10.1182/blood.V97.4.835.
143. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, et al. Adoptive T cell therapy using antigenspecific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002; 99:16168-73; PMID:12427970; http://dx.doi.org/10.1073/pnas.242600099.
144. Spiotto MT, Rowley DA, Schreiber H. Bystander elimination of antigen loss variants in established tumors. Nat Med 2004; 10:294-8; PMID:14981514; http://dx.doi.org/10.1038/nm999.
145. Ngoi SM, St Rose MC, Menoret AM, Smith DE, Tovey MG, Adler AJ, et al. Presensitizing with a Tolllike receptor 3 ligand impairs CD8 T-cell effector differentiation and IL-33 responsiveness. Proc Natl Acad Sci U S A 2012; 109:10486-91; PMID:22689946; http://dx.doi.org/10.1073/pnas.1202607109.
146. Lüthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009; 31:84-98; PMID:19559631; http://dx.doi.org/10.1016/j.immuni.2009.05.007.
147. Bonilla WV, Fröhlich A, Senn K, Kallert S, Fernandez M, Johnson S, et al. The alarmin interleukin-33 drives protective antiviral CD8+ T cell responses. Science 2012; 335:984-9; PMID:22323740; http://dx.doi.org/10.1126/science.1215418.
148. Lacy MQ, Jacobus S, Blood EA, Kay NE, Rajkumar SV, Greipp PR. Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group. Leuk Res 2009; 33:1485-9; PMID:19243818; http://dx.doi.org/10.1016/j.leukres.2009.01.020.
149. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol 1996; 19:81-4; PMID:8859727; http://dx.doi.org/10.1097/00002371-199601000-00009.
150. Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med 2000; 192:1637-44; PMID:11104805; http://dx.doi.org/10.1084/jem.192.11.1637.
151. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006; 24:2283-9; PMID:16710025; http://dx.doi.org/10.1200/JCO.2005.04.5716.
152. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 2008; 105:14987-92; PMID:18818309; http://dx.doi.org/10.1073/pnas.0806075105.
153. Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 2009; 361:211-2; PMID:19587352; http://dx.doi.org/10.1056/NEJMc0904283.
154. Carthon BC, Wolchok JD, Yuan J, Kamat A, Ng Tang DS, Sun J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 2010; 16:2861-71; PMID:20460488; http://dx.doi.org/10.1158/1078-0432.CCR-10-0569.
155. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466.
156. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355:1018-28; PMID:16908486; http://dx.doi.org/10.1056/NEJMoa063842.
157. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010; 37:508-16; PMID:21074066; http://dx.doi.org/10.1053/j.seminoncol. 2010.09.008.
158. Van Assche G, Rutgeerts P. Anti-TNF agents in Crohn's disease. Expert Opin Investig Drugs 2000; 9:103-11; PMID:11060664; http://dx.doi.org/10.1517/13543784.9.1.103.
159. Kober J, Leitner J, Klauser C, Woitek R, Majdic O, Stöckl J, et al. The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur J Immunol 2008; 38:2678-88; PMID:18825741; http://dx.doi.org/10.1002/eji.200838250.
160. Ma BY, Mikolajczak SA, Danesh A, Hosiawa KA, Cameron CM, Takaori-Kondo A, et al. The expression and the regulatory role of OX40 and 4-1BB heterodimer in activated human T cells. Blood 2005; 106:2002-10; PMID:15941918; http://dx.doi.org/10.1182/blood-2004-04-1622.
161. Kober J, Leitner J, Klauser C, Woitek R, Majdic O, Stöckl J, et al. The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur J Immunol 2008; 38:2678-88; PMID:18825741; http://dx.doi.org/10.1002/eji.200838250.
162. Serghides L, Bukczynski J, Wen T, Wang C, Routy JP, Boulassel MR, et al. Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7.1 and 4-1BBL. J Immunol 2005; 175:6368-77; PMID:16272289.
163. Sawyers CL. Making progress through molecular attacks on cancer. Cold Spring Harb Symp Quant Biol 2005; 70:479-82; PMID:16869786; http://dx.doi.org/10.1101/sqb.2005.70.034.
164. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468:973-7; PMID:21107323; http://dx.doi.org/10.1038/nature09626.
165. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18:683-95; PMID:21156289; http://dx.doi.org/10.1016/j. ccr.2010.11.023.
166. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468:968-72; PMID:21107320; http://dx.doi.org/10.1038/nature09627.
167. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694.
168. Hurwitz AA, Yu TF, Leach DR, Allison JP. CTLA-4 blockade synergizes with tumor-derived granulocytemacrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A 1998; 95:10067-71; PMID:9707601; http://dx.doi.org/10.1073/pnas.95.17.10067.
169. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000; 60:2444-8; PMID:10811122.
170. Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 2011; 6:e19499; PMID:21559358; http://dx.doi.org/10.1371/journal.pone.0019499.
171. Sierro SR, Donda A, Perret R, Guillaume P, Yagita H, Levy F, et al. Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces antitumor immunity. Eur J Immunol 2011; 41:2217-28; PMID:21538347; http://dx.doi.org/10.1002/eji.201041235.
172. Borrello I, Sotomayor EM, Rattis FM, Cooke SK, Gu L, Levitsky HI. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 2000; 95:3011-9; PMID:10807763.
173. Nigam A, Yacavone RF, Zahurak ML, Johns CM, Pardoll DM, Piantadosi S, et al. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int J Oncol 1998; 12:161-70; PMID:9454900.
174. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001; 61:3689-97; PMID:11325840.
175. Dummer W, Niethammer AG, Baccala R, Lawson BR, Wagner N, Reisfeld RA, et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest 2002; 110:185-92; PMID:12122110.
176. Hu HM, Poehlein CH, Urba WJ, Fox BA. Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res 2002; 62:3914-9; PMID:12124318.
177. Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, Belardelli F, et al. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 2000; 95:2024-30; PMID:10706870.
178. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumorspecific CD8 T cells. J Immunol 2003; 170:4905-13; PMID:12734333.
179. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202:1691-701; PMID:16365148; http://dx.doi.org/10.1084/jem.20050915.
180. Hirschhorn-Cymerman D, Rizzuto GA, Merghoub T, Cohen AD, Avogadri F, Lesokhin AM, et al. OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med 2009; 206:1103-16; PMID:19414558; http://dx.doi.org/10.1084/jem.20082205.
181. Hirschhorn-Cymerman D, Budhu S, Kitano S, Liu C, Zhao F, Zhong H, et al. Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. J Exp Med 2012; 209:2113-26; PMID:23008334; http://dx.doi.org/10.1084/jem.20120532.
182. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29; PMID:22237781; http://dx.doi.org/10.3322/caac.20138.
183. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer 2002; 2:389-96; PMID:12044015; http://dx.doi.org/10.1038/nrc801.
184. Hakimi JM, Rondinelli RH, Schoenberg MP, Barrack ER. Androgen-receptor gene structure and function in prostate cancer. World J Urol 1996; 14:329-37; PMID:8912473; http://dx.doi.org/10.1007/BF00184606.
185. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10:33-9; PMID:14702632; http://dx.doi.org/10.1038/nm972.
186. Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005; 7:239-49; PMID:15766662; http://dx.doi.org/10.1016/j.ccr.2005.01.027.
187. Antonarakis ES, Drake CG. Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy. Curr Opin Oncol 2012; 24:258-65; PMID:22410456; http://dx.doi.org/10.1097/CCO.0b013e32835205a0.
188. Sutherland JS, Goldberg GL, Hammett MV, Uldrich AP, Berzins SP, Heng TS, et al. Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol 2005; 175:2741-53; PMID:16081852.
189. Bansal-Pakala P, Jember AG, Croft M. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat Med 2001; 7:907-12; PMID:11479622; http://dx.doi.org/10.1038/90942.
190. Redmond WL, Gough MJ, Weinberg AD. Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo. Eur J Immunol 2009; 39:2184-94; PMID:19672905.